Patent ID: 7960380
Filing Date: 2011-06-14
Classification: A61P,C07D

Abstract:
1. A method of treating atherosclerosis comprising the administration of a thereapeutically effective amount of a compound of Formula I, or a suitable pharmaceutically acceptable salt thereof, to a mammal in need thereof, wherein: R 1 represents: X which is optionally substituted by one or more of the following independently selected from: F, OH, CN, NR cycloalkyl or heterocyclyl each optionally substituted by one or more of the following independently selected from: F, OH, CN, NR phenyl or heteroaryl each optionally substituted by one or more of the following independently selected from: halogen, OH, CN, NO cycloalkylY or heterocyclylY wherein cycloalkyl or heterocyclyl each optionally is substituted by one or more of the following independently selected from: F, OH, CN, NR phenylY or heteroarylY wherein phenyl or heteroaryl each optionally is substituted by one or more of the following independently selected from: halogen, OH, CN, NO R 2 represents: phenyl which is optionally substituted by one or more of the following independently selected from: halogen, OH, CN, NO R 3 represents: X which is optionally substituted by one or more of the following independently selected from: F, OH, CN, NR MP or Het AP or Het E or Het and further wherein: X represents a straight or branched, saturated or unsaturated alkyl group having 1 to 6 carbon atoms wherein said alkyl group may optionally be interrupted by O, S, SiR Y which binds to the nitrogen in the 2-position of the isothiazol-3(2H)-one 1,1-dioxide and represents a straight or branched, saturated or unsaturated alkylene group having 1 to 3 carbon atoms wherein said alkyl group may optionally be interrupted or ended by one of the following: O, S, SiR Z binds to E or Het M represents a saturated or unsaturated non-aromatic monocarbocyclic ring composed of 3, 4, 5, 6, 7 or 8 carbon atoms or a saturated or unsaturated non-aromatic or partly aromatic bicyclic ring system composed of 8, 9 or 10 carbon atoms; E represents a saturated or unsaturated non-aromatic monocarbocyclic ring composed of 3, 4, 5, 6, 7 or 8 carbon atoms or a saturated or unsaturated non-aromatic or partly aromatic bicyclic ring system composed of 8, 9 or 10 carbon atoms, and the ring binds, unless otherwise specified, through its non-aromatic part to the amine group bonded to the 4-position on the isothiazol-3(2H)-one 1,1-dioxide; A represents an aromatic monocyclic ring composed of 6 carbon atoms or an aromatic bicyclic ring system composed of 10 carbon atoms; P binds to the amine group bonded to the 4-position on the isothiazol-3(2H)-one 1,1-dioxide and represents a straight or branched, saturated or unsaturated alkylene group having 1 to 6 carbon atoms wherein the alkylene group is optionally interrupted or ended by one of the following: O, NR Q represents a saturated or unsaturated non-aromatic monocyclic ring composed of 3, 4, 5, 6, 7 or 8 carbon atoms, which is optionally substituted by one or more of the following independently selected from: F, OH, CN, NR R represents a phenyl group which is optionally substituted by one or more of the following independently selected from: halogen, OH, CN, NO T binds to M, Het Het Het Het Het Het R R R